Research graph
References from Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma. Local targets link to admitted publications; unresolved targets remain external evidence.
Teclistamab plus daratumumab in relapsed or refractory multiple myeloma
10.1056/nejmoa2514663 · 2026 · External reference
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis
10.1016/j.jgo.2023.101628 · 2024 · External reference
Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: a CIBMTR analysis
10.1182/blood-2025-133 · 2025 · External reference
Unresolved reference
External reference
10.1182/bloodadvances.2026019898 · Admitted local publication
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
10.1016/s1470-2045(25)00653-9 · 2026 · External reference
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
10.1038/s41375-022-01531-2 · 2022 · External reference
Retreatment with anti-CD38-based combinations in multiple myeloma in real-life: results from the Emmy cohort study
10.1016/j.clml.2025.05.015 · 2025 · External reference
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
10.1182/bloodadvances.2023010162 · 2023 · External reference
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
10.1182/blood-2016-03-703439 · 2016 · External reference
Safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
10.1182/blood.2024025945 · 2025 · External reference
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
10.1038/s41408-024-01167-8 · 2024 · External reference
CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
10.1056/nejmoa2411507 · 2025 · External reference
Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel
10.1038/s41408-024-01129-0 · 2024 · External reference
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience
10.1038/s41408-023-00963-y · 2023 · External reference
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing
10.1002/hem3.132 · 2024 · External reference
Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels
10.1182/bloodadvances.2025016490 · 2025 · External reference
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma
10.1182/blood-2025-5814 · 2025 · External reference
International Myeloma Working Group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
10.1038/s41375-024-02482-6 · 2025 · External reference
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
10.1038/s41591-023-02491-5 · 2023 · External reference
